Fasting and fasting-mimicking diets around chemotherapy
Eating very little for a few days around each chemotherapy dose might protect normal cells and sensitise the tumour. Early trials are intriguing but small, and it is not something to try without a dietitian.
Short-term fasting lowers glucose, insulin and IGF-1 and shifts normal cells into a protective, low-proliferation state ('differential stress resistance') while cancer cells, unable to slow down, may become more chemosensitive. Mouse data are strong. In humans, the DIRECT trial (Netherlands, 131 patients with HER2-negative early breast cancer, Nature Communications 2020) randomised a plant-based fasting-mimicking diet for three days before and on the day of each neoadjuvant chemotherapy cycle: radiological response was better (OR 3.2) and a 90-100% tumour cell loss more frequent in the diet arm, but adherence collapsed (fewer than 20% completed all cycles) and pathological complete response did not differ. Phase 2 trials in breast, colorectal and lung cancer are running; none has a survival endpoint yet. Weight loss and sarcopenia are real risks, and fasting is contraindicated in cachexia.
How it works
Nutrient deprivation lowers systemic growth signalling (insulin, IGF-1) and induces protective stress responses in normal tissue, potentially widening the therapeutic window of cytotoxics.
- Strong preclinical rationale
- Randomised signal on radiological response in DIRECT
- Very cheap
- Adherence is poor
- No survival or pCR benefit shown
- Risk of muscle loss; unsuitable for malnourished patients
Latest papers
topQuery for this technology: (TITLE:"Fasting and fasting-mimicking diets around chemotherapy" OR ABSTRACT:"Fasting and fasting-mimicking diets around chemotherapy") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Fasting and fasting-mimicking diets around chemotherapy, not a curated reading list.
Pages like this
not linked directly; found by shared links- IdeaPerioperative beta-blocker plus COX-2 inhibitor to reduce metastasis after surgery
Shares No incentive to repurpose cheap drugs, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- TrialAdd-Aspirin
Shares No incentive to repurpose cheap drugs, Funding follows fashion, not burden, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- TermGlycaemic index and glycaemic load
Shares Warburg-effect diet claims ('sugar feeds cancer'), Energy balance, Colorectal cancer.
- IdeaA public fund and label pathway to trial generic drugs against cancer
Shares No incentive to repurpose cheap drugs, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- IdeaOne definitive ketogenic diet trial in glioblastoma, then stop
Shares Warburg-effect diet claims ('sugar feeds cancer'), Metabolic therapy: starving the tumour of a nutrient, Funding follows fashion, not burden.
- IdeaA public fund that pays for phase 3 trials of cheap, off-patent drugs against cancer
Shares No incentive to repurpose cheap drugs, Funding follows fashion, not burden.
- IdeaA social impact bond: investors fund a repurposing trial, payers repay from savings
Shares No incentive to repurpose cheap drugs, Funding follows fashion, not burden.
- IdeaCheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress
Shares No incentive to repurpose cheap drugs, HR-positive / HER2-negative breast cancer, Colorectal cancer.